WealthStone’s Regeneron Pharmaceuticals REGN Stock Holding History

WealthStone’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-13	Closed	-$4.07K	–	481
2019 Q2	$4.07K	Buy	+13	New	+$4.33K	﹤0.01%	382

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

WealthStone's REGN Position: Q3 2019 in Review

WealthStone sold out of Regeneron Pharmaceuticals (REGN) in Q3 2019, closing a stake of 13 shares — an estimated $4.07K sold.

WealthStone first reported a position in REGN in Q2 2019 and held it in 1 quarter. The position peaked at $4.07K in Q2 2019. 632 funds tracked by Wall St. Rank hold REGN as of Q3 2019.

WealthStone reported no remaining Regeneron Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
WealthStone sold 13 Regeneron Pharmaceuticals shares in Q3 2019, an estimated $4.07K.
WealthStone first reported a position in Regeneron Pharmaceuticals in Q2 2019 and held it in 1 quarter.
WealthStone's Regeneron Pharmaceuticals position peaked at $4.07K in Q2 2019.
632 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2019.

Based on WealthStone's 13F filing for Q3 2019, filed 15 Nov 2019.